A total of 633 biotechnology medicines for more than 100 diseases are currently in development, according to the Pharmaceutical Research and Manufacturers of America (PhRMA). By therapeutic category, with some medicines counted in more than one category, the number of biotech medicines in development for cancer and related conditions, at 254, and infectious disease, at 162, dwarf all other disease areas. The next three largest therapeutic categories are autoimmune disorders, with 59 biotech medicines in development, HIV/AIDS infection and related conditions, with 34 in development, and respiratory disorders, with 27 in development. By product category: vaccines account for 223 of the biotech medicines in development, monoclonal antibodies account for 192, recombinant hormones/proteins, account for 66, gene therapy accounts for 38, and cell therapy accounts for 23.

Source: PhRMA

< | >